Tocilizumab in systemic sclerosis: A randomised, double-blind, placebo-controlled, Phase 3 trial
Lancet Respir Med 2020;8:963–74 DOI: 10.1016/S2213-2600(20)30318-0.
Khanna et al. evaluated tocilizumab in patients with early diffuse cutaneous systemic sclerosis in the focuSSced trial. The primary endpoint of improved skin fibrosis was not met, but a key secondary outcome showed that tocilizumab significantly preserved lung function compared with placebo.
This Phase 3 trial enrolled 210 participants across 75 sites and randomised them to weekly SC tocilizumab or placebo for 48 weeks. The trial aimed to assess the efficacy of tocilizumab in reducing skin thickening and preventing decline in lung function in individuals with early active systemic sclerosis.
Keywords:
